Ide-cel or Standard Regimens in Relapsed and Refractory Multiple MyelomaPaula Rodríguez‐Otero, Sergio Giralt, Salomon Manier et al.|New England Journal of Medicine|2023Cited by 695
Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 studyMichel Attal, Michel Pavic, Paul G. Richardson et al.|The Lancet|2019Cited by 635
Combining conventional therapy with immunotherapy: A risky business?An Coosemans, Ignace Vergote, Ann Vankerckhoven et al.|European Journal of Cancer|2019Cited by 31